GZGuangyong Zou

Guangyong Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guangyong Zou has a total of 238 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Definition, analysis, reporting, and interpretation of perioperative bleeding in randomized controlled trials: a methodological systematic review

    by Yasaman Mohammadi Kamalabadi, Guangyong Zou, Maha El-Shimy, Natalie Mariam Zitoun, Justyna Bartoszko, Pavel S. Roshanov

    Background: Perioperative bleeding is a common surgical complication and a frequently used outcome in randomized trials; however, its definition and analysis are not straightforward and have important implications for trial design, statistical power and interpretation of treatment effect. This review aimed to summarize how perioperative bleeding was defined in randomized controlled trials, along with sample size considerations, analytic approaches, and interpretation practices. Methods: On April 9th, 2025, we systematically searched the CENTRAL database for randomized trials in surgical settings published after January 2024 that evaluated perioperative bleeding as the primary outcome. Two reviewers independently screened and extracted data. Where appropriate, we categorized findings into conceptually similar domains and applied descriptive analysis. Results: We included 115 trials reporting 116 primary bleeding outcomes and identified 36 unique definitions, with assessment periods ranging from intraoperative to more than 30 days postoperatively. Volumetric or gravimetric measures were most common ( n = 46 [39.6%]), whereas patient-reported events ( n = 5 [4.3%]) and clinical management of blood loss ( n = 4 [3.4%]) were rare. Most trials reported a sample size calculation based on the primary outcome ( n = 90 [78.3%]), but over one-third lacked effect-size justification ( n = 34 [37.8%]). Analyses were predominantly parametric ( n = 69 [59.5%]), while a few adjusted for baseline covariates ( n = 18 [15.6%]). Interpretation in superiority trials relied mainly on statistical significance ( n = 49 [47.6%]). Among noninferiority trials, noninferiority was often claimed without prespecified margins ( n = 4 [33.3%]). Conclusion: Perioperative bleeding outcomes are defined and analyzed with high inconsistency. Standardized outcome definitions and reporting practices are needed in this field to improve trial comparability and clinical relevance.

  • An Enhanced Treatment Algorithm Targeting Mucosal Healing is Effective and Safe in Older Patients with Crohn’s Disease: A Post-hoc Analysis of the REACT2 Trial.

    by Shane W Goodwin, Sudheer Kumar Vuyyuru, Rocio Sedano, Guangyong Zou, Parambir S. Dulai, Siddarth Singh, Neeraj Narula, Christopher Ma, Vipul Jairath

    Introduction: Safety and effectiveness of treating to target mucosal healing in older patients with Crohn’s disease (CD) is unknown. Methods: We analyzed CD-related complications by 24 months in the REACT-2 trial that randomized practices to an enhanced-care or step-care algorithm to determine whether patient age modifies the effect of treatment. Data were analyzed using marginal Cox regression and modified Poisson regression. Results: There was no difference in treatment between younger and older patients in at 24 months. Discussion: EC was effective and not associated with increased risk compared with SC in older patients with Crohn’s disease.

  • Open Access

    Synergistic effects of exercise, cognitive training and vitamin D on gait performance and falls in mild cognitive impairment—secondary outcomes from the SYNERGIC trial

    by Frederico Pieruccini-Faria, Surim Son, Guangyong Zou, Quincy J Almeida, Laura E Middleton, Nick W Bray, Maxime Lussier, J Kevin Shoemaker, Mark Speechley, Teresa Liu-Ambrose, et al.

    Background: Older adults with mild cognitive impairment (MCI) have a higher risk of gait impairments and falls; yet, the effects of multimodal interventions, including combinations of exercises with cognitive training, on improving their mobility remain unclear. Objectives: To investigate the synergistic effects of aerobic-resistance exercise combined with cognitive training, with or without vitamin D supplementation, on gait performance and falls risk in older adults with MCI. Methods: The effect of 20 weeks of aerobic-resistance exercise, cognitive training, and Vitamin D supplementation (10 000 IU 3×/week) on gait and falls in older adults with MCI was evaluated in the SYNERGIC trial, using a fractional factorial design. Assessments were conducted at baseline, 6-month endpoint (after intervention) and 12-month endpoint (follow-up). Eligible participants were between the ages of 65 and 84 years with MCI enrolled from 19 September 2016 to 7 April 2020. Main outcomes of interest for gait performance were gait speed and gait variability changes, whilst for falls were incidental falls and incidental injurious falls. Results: Amongst 161 participants, the four exercise-based arms improved gait speed (+7.5 cm/s, P < .001) and reduced falls (incidence rate ratios (IRR) = 0.65, 95% confidence interval (CI): 0.32–1.42, P = .25) and injurious falls (IRR = 0.38, 95% CI: 0.15–1.05, P = .05) at 6-month endpoint. Falls reduction reached statistical significance (IRR = 0.28, 95% CI: 0.13–0.64, P = .002) at 12-month endpoint. Exercises combined with cognitive training showed the greatest gains in gait speed at 6-month endpoint (P < .001) and in reducing falls at 12-month endpoint (IRR = 0.24, 95% CI: 0.05–0.77, P = .02) compared to the control. Vitamin D did not enhance outcomes and increased gait variability, a marker of instability. Conclusion: Aerobic-resistance exercise combined with sequential computerised cognitive training improved gait performance at 6 months and decreased the risk of falls and injuries at 12 months in older adults with MCI. The addition of vitamin D did not produce benefits.


  • Open Access

    Young adults with type 2 diabetes experience high rates of Level 3 Hypoglycemia: A subgroup analysis of the Real-World iNPHORM cohort

    by Yu Kuei Lin, Jason E. Black, Stewart B Harris, Bridget L. Ryan, Guangyong Zou, Alexandria Ratzki-Leewing


  • Open Access

    Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

    by Siddharth Singh, Jasmine D Nguyen, David I Fudman, Mark E Gerich, Samir A Shah, David Hudesman, Ryan A McConnell, Dana J Lukin, Ann D Flynn, Caroline Hwang, et al.

    Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. Methods and analysis The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. Ethics and dissemination The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn’s & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). Trial registration number NCT05230173.


  • Predicting Health Utilities Using Health Administrative Data: Leveraging Survey-linked Health Administrative Data from Ontario, Canada

    by Yue Niu, Nazire Begen, Guangyong Zou, Sisira Sarma

    Background The quality-adjusted life year (QALY) is widely used to measure health outcome that combines the length of life and health-related quality of life (HRQoL). To be a reliable QALY measure, HRQoL measurements with a preference-based scoring algorithm need to be converted into health utilities on a scale from zero (dead) to one (perfect health). However, preference-based health utility data are often not available. We address this gap by developing a predictive model for health utilities. Objectives To develop a predictive model for health utilities using available demographic and morbidity variables in a health administrative dataset for non-institutionalised populations in Ontario, Canada. Methods The data were obtained from the 2009 to 2010 Canadian Community Health Survey containing Health Utilities Index Mark3 (HUI3), a generic multi-attribute preference-based health utility instrument linked with Ontario health administrative (OHA) data that were collected for administrative or billing purposes for patient encounters with the health care system. We employed four regression models (linear, Tobit, single-part beta mixture, and two-part beta mixture) and a calibration technique to identify the best-fit regression model. Results Our findings indicate that the two-part beta mixture model is the best-fit for predicting health utilities in the OHA data. The proposed predictive model reflects the original distribution of HUI3 in the population. Conclusion Our proposed predictive model generates reasonably accurate health utility predictions from OHA data. Our model-based prediction approach is a useful strategy for real-world applications, particularly when preference-based utility data are unavailable.

  • Open Access

    A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin

    by Guangyong Zou, Lily Zou

    Multiple primary endpoints are commonly used in randomized controlled trials to assess treatment effects. When the endpoints are measured on different scales, the O'Brien rank‐sum test or the Wei–Lachin test for stochastic ordering may be used for hypothesis testing. However, the O'Brien–Wei–Lachin (OWL) approach is unable to handle missing data and adjust for baseline measurements. We present a nonparametric approach for data analysis that encompasses the OWL approach as a special case. Our approach is based on quantifying an endpoint‐specific treatment effect using the probability that a participant in the treatment group has a better score than (or a win over) a participant in the control group. The average of the endpoint‐specific win probabilities (WinPs), termed the global win probability (gWinP), is used to quantify the global treatment effect, with the null hypothesis gWinP = 0.50. Our approach involves converting the data for each endpoint to endpoint‐specific win fractions, and modeling the win fractions using multivariate linear mixed models to obtain estimates of the endpoint‐specific WinPs and the associated variance–covariance matrix. Focusing on confidence interval estimation for the gWinP, we derive sample size formulas for clinical trial design. Simulation results demonstrate that our approach performed well in terms of bias, interval coverage percentage, and assurance of achieving a pre‐specified precision for the gWinP. Illustrative code for implementing the methods using SAS PROC RANK and PROC MIXED is provided.


  • Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease

    by Florian Rieder, Mark E. Baker, David H. Bruining, Jeff L. Fidler, Eric C. Ehman, Shannon P. Sheedy, Jay P. Heiken, Justin M. Ream, David R. Holmes, Akitoshi Inoue, et al.

    Stricture length, maximal stricture wall thickness, and maximal associated small bowel dilation at MR enterography can reliably assess Crohn disease stricture severity and serve as eligibility and efficacy criteria in clinical trials.


  • Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease

    by Florian Rieder, Christopher Ma, Jurij Hanzel, Joel G. Fletcher, Mark E. Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M. Shackelton, Julie Rémillard, Mihir Patel, et al.

    Maximal associated small bowel dilation, stricture length, and maximal stricture wall thickness at CT enterography can reliably describe Crohn disease stricture severity and serve as eligibility or efficacy criteria in antistricture therapy trials.